Jointown Pharmaceutical Group Co., Ltd. Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Million

Consolidate Quarterly Results

Mar'26

Dec'25

Sep'25

Jun'25

Mar'25

Dec'24

Sep'24

Net Sales

44,782.65

42,063.42

38,220.37

39,090.03

42,016.18

38,380.75

36,258.17

Other Operating Income

0.00

Total Operating income

44,782.65

42,063.42

38,220.37

39,090.03

42,016.18

38,380.75

36,258.17

Raw Material Cost

41,439.80

38,944.73

35,261.29

36,199.83

39,099.51

35,732.32

33,494.96

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

319.03

262.58

245.91

255.92

249.39

305.59

328.59

Selling and Distribution Expenses

2,302.06

2,202.83

1,928.65

1,884.85

1,898.34

1,706.33

1,755.17

Other Expenses

-29.48

-23.47

-21.80

-22.84

-21.64

-25.78

-29.80

Total Expenditure (Excl Depreciation)

43,766.11

41,175.48

37,217.82

38,112.16

41,030.81

37,486.40

35,280.70

Operating Profit (PBDIT) excl Other Income

1016.5

887.9000000000001

1002.6

977.9000000000001

985.4000000000001

894.3000000000001

977.5

Other Income

-84.56

42.80

6.52

75.18

640.78

877.45

75.88

Operating Profit (PBDIT)

771.62

966.22

1,123.59

1,141.49

1,724.46

1,859.28

1,163.38

Interest

319.03

262.58

245.91

255.92

249.39

305.59

328.59

Exceptional Items

263.27

-3.17

3.84

53.14

-1.91

-4.33

0.97

Gross Profit (PBDT)

3,342.85

3,118.69

2,959.07

2,890.20

2,916.66

2,648.43

2,763.22

Depreciation

0.00

208.64

239.45

234.52

Profit Before Tax

715.86

491.83

672.88

699.26

1,233.70

1,314.83

601.23

Tax

167.28

258.61

148.37

211.75

261.49

336.95

108.89

Provisions and contingencies

0.00

Profit After Tax

733.16

279.41

529.89

475.70

969.86

811.20

488.55

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

733.16

279.41

529.89

475.70

969.86

811.20

488.55

Share in Profit of Associates

0.00

Minority Interest

-137.97

52.96

28.54

29.19

44.03

204.21

31.94

Other related items

0.00

Consolidated Net Profit

595.19

332.37

558.43

504.90

1,013.88

1,015.41

520.49

Equity Capital

0.00

Face Value

1.0

Reserves

27,509.66

26,782.95

26,477.26

25,998.54

26,457.79

25,471.29

24,656.92

Earnings per share (EPS)

0.15

0.06

0.11

0.1

0.19

0.16

0.1

Diluted Earnings per share

0.15

0.06

0.11

0.1

0.19

0.16

0.1

Operating Profit Margin (Excl OI)

1.91%

1.7%

2.38%

2.12%

2.01%

1.95%

2.35%

Gross Profit Margin

1.6%

1.67%

2.31%

2.4%

3.51%

4.04%

2.31%

PAT Margin

1.64%

0.66%

1.39%

1.22%

2.31%

2.11%

1.35%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Quarterly Analysis Highlights - QoQ

Net Sales

QoQ Growth in quarter ended Mar 2026 is 6.46% vs 10.05% in Dec 2025

Consolidate Net Profit

QoQ Growth in quarter ended Mar 2026 is 79.06% vs -40.47% in Dec 2025

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Mar 2026 is -7.28% vs -17.34% in Dec 2025

Interest

QoQ Growth in quarter ended Mar 2026 is 21.48% vs 6.79% in Dec 2025

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025

Compare Quarterly Results Of Jointown Pharmaceutical Group Co., Ltd. With

Select Peers

Figures in Million

Consolidate Quarterly Results

Change(CNY)

Change(%)

Net Sales

44,782.65

Other Operating Income

0.00

Total Operating income

44,782.65

Raw Material Cost

41,439.80

Purchase of Finished goods

0.00

(Increase) / Decrease In Stocks

0.00

Employee Cost

0.00

Power Cost

0.00

Manufacturing Expenses

319.03

Selling and Distribution Expenses

2,302.06

Other Expenses

-29.48

0.00

-29.48

Total Expenditure (Excl Depreciation)

43,766.11

Operating Profit (PBDIT) excl Other Income

1,016.54

0.00

1,016.54

Other Income

-84.56

Operating Profit (PBDIT)

771.62

Interest

319.03

Exceptional Items

263.27

Gross Profit (PBDT)

3,342.85

Depreciation

0.00

Profit Before Tax

715.86

Tax

167.28

Provisions and contingencies

0.00

Profit After Tax

733.16

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

733.16

Share in Profit of Associates

0.00

Minority Interest

-137.97

Other related items

0.00

Consolidated Net Profit

595.19

Equity Capital

0.00

Face Value

1.00

0.00

Reserves

27,509.66

Earnings per share (EPS)

0.15

Diluted Earnings per share

0.15

Operating Profit Margin (Excl OI)

1.91%

0.00

1.91%

Gross Profit Margin

1.60%

0.00

1.60%

PAT Margin

1.64%

0.00

1.64%

Public Share Holdings (%)

0.00

0.00%

Pledged Promotor Holding (%)

0.00

0.00%

Quarterly - Net Sales

Net Sales 4,478.26 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is 6.46% vs 10.05% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 6.58% vs 4.09% in Mar 2025

Quarterly - Consolidate Net Profit

Consolidate Net Profit 59.52 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is 79.06% vs -40.47% in Dec 2025

YoY Growth in quarter ended Mar 2026 is -41.30% vs 87.00% in Mar 2025

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 85.62 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is -7.28% vs -17.34% in Dec 2025

YoY Growth in quarter ended Mar 2026 is -20.99% vs -2.78% in Mar 2025

Quarterly - Interest

Interest 31.90 Million

in Mar 2026

Figures in Million

QoQ Growth in quarter ended Mar 2026 is 21.48% vs 6.79% in Dec 2025

YoY Growth in quarter ended Mar 2026 is 27.91% vs -20.95% in Mar 2025

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 1.91%

in Mar 2026

Figures in %

QoQ Growth in quarter ended Mar 2026 has improved from Dec 2025

YoY Growth in quarter ended Mar 2026 has fallen from Mar 2025